85%Confidence
0Views
FDASource
2026-03-03Date
Summary
Fresenius Kabi Compounding faces a Class II recall for thiamine HCl due to sterility assurance issues, highlighting compounding pharmacy risks. This could impact hospital and clinic confidence in outsourced sterile preparations.
Actionable: Review all Fresenius Kabi Compounding products in inventory and consider alternative sterile compounding providers.
AI Confidence: 85%
Data Points
firmFresenius Kabi Compounding, LLC
classificationClass II
statusOngoing
distributionUS Nationwide.
productthiamine HCl, 500 mg, 500 mg added to 100 mL, 0.9% Sodium Chloride Injection, USP, Fagron Sterile Services, 20 Dan Road, Canton, MA 02021, NDC 71506-0
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now